STOCK TITAN

ProMIS Neurosciences (PMN): Wellington group discloses 7.77% ownership stake

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

ProMIS Neurosciences, Inc. has a Schedule 13G/A filed by several Wellington entities reporting a passive ownership position in the company’s common stock as of June 30, 2026. Wellington Management Group LLP and related holding and advisory entities report beneficial ownership of 696,378 shares of ProMIS common stock, representing 7.77% of the class. The Wellington entities report no sole voting or dispositive power, but shared voting and shared dispositive power over all 696,378 shares. The shares are held of record by clients of one or more Wellington investment advisers, including certain Wellington Biomedical Innovation Master Investors funds that may each hold more than five percent of the class at the client level.

Positive

  • None.

Negative

  • None.
Shares beneficially owned 696,378 shares Beneficially owned by Wellington entities as of June 30, 2026
Percent of class 7.77% ProMIS Neurosciences common stock held by Wellington entities
Shared voting power 696,378 shares Shares over which Wellington entities have shared voting power
Shared dispositive power 696,378 shares Shares over which Wellington entities have shared dispositive power
Ownership threshold exceeded 5% Schedule 13G/A filing triggered by holding more than 5% of class
Reporting entities 4 entities Wellington Management Group LLP and three related entities reporting
beneficially owned financial
"Amount beneficially owned: See the responses to Item 9 on the attached cover pages."
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared voting power financial
"Shared Voting Power 696,378.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power financial
"Shared Dispositive Power 696,378.00"
parent holding company financial
"Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company"
investment advisers financial
"The securities as to which this Schedule is filed are owned of record by clients of one or more investment advisers"

FAQ

What ownership stake in ProMIS Neurosciences (PMN) do the Wellington entities report?

The Wellington entities report beneficial ownership of 696,378 shares of ProMIS Neurosciences common stock, representing 7.77% of the outstanding class as of June 30, 2026, held for various advisory clients.

Which Wellington entities are listed as reporting persons for ProMIS Neurosciences (PMN)?

The filing lists Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP as reporting persons, reflecting the Wellington ownership and advisory structure over the ProMIS position.

How much voting power do the Wellington entities have over ProMIS Neurosciences (PMN) shares?

The Wellington entities report 0 shares with sole voting power and 696,378 shares with shared voting power, indicating voting authority is shared, typically with advisory clients or related entities, rather than held solely by a single Wellington entity.

Do Wellington’s clients, rather than Wellington itself, own the ProMIS Neurosciences (PMN) shares?

Yes. The shares are owned of record by clients of one or more Wellington investment advisers. Those clients have the right to receive dividends and sale proceeds, while Wellington reports beneficial ownership through its advisory and holding structure.

Which Wellington client funds may each hold over 5% of ProMIS Neurosciences (PMN)?

The filing notes that no client is known to hold over 5% of the class, except potentially Wellington Biomedical Innovation Master Investors (Cayman) II L.P. and Wellington Biomedical Innovation Master Investors (Cayman) II, L.P..

Is the Wellington stake in ProMIS Neurosciences (PMN) reported as passive or activist?

This is filed on Schedule 13G/A, which is typically used for passive beneficial ownership rather than an activist position, indicating Wellington’s stake is reported in a non-control, investment capacity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





74346M505

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Wellington Management Group LLP
Signature:Matthew Revell
Name/Title:Compliance Manager
Date:08/14/2026
Wellington Group Holdings LLP
Signature:Matthew Revell
Name/Title:Compliance Manager
Date:08/14/2026
Wellington Investment Advisors Holdings LLP
Signature:Matthew Revell
Name/Title:Compliance Manager
Date:08/14/2026
Wellington Management Company LLP
Signature:Matthew Revell
Name/Title:Compliance Manager
Date:08/14/2026